[DISCLOSURE] Yungjin Pharmaceutical
(003520) announced on March 20 that it has renewed its contract with Japan’s Sawai Pharmaceutical to exclusively supply oral antibiotics.
The contract is worth 181.6 billion won (US$162.72 million), amounting to 106.7 percent of its 2015 revenue. It is valid until Dec. 31, 2021, to be automatically renewed every year without objection from either party.
By Hwang You-mee (firstname.lastname@example.org